Metabolic syndrome (MS) is a clinical syndrome in which certain high-risk environmental factors are the initiating factors, abdominal obesity is the main pathogenesis, insulin resistance (IR) is the important pathogenic link, and cardiovascular damage is the serious consequence. The incidence of diabetes mellitus (DM) and cardiovascular disease in MS patients is often several times higher than that in the normal population, especially in the elderly, and the problem of aging is becoming increasingly serious, making MS a worldwide public health problem. The 2000 US census showed that MS has affected 24% of adults (aged 20-70 years) and the incidence of MS is increasing [1]. Epidemiological data in China show that the prevalence of MS in the general population is 13.25% and increases with age, with the prevalence of MS in people aged 45 and 55 years or older being 2 and 2.8 times higher than that in people aged 35 years or older, respectively, and the prevalence in people aged 55 years or older being as high as 20.26% [2]. Age is an important factor in metabolic syndrome, which may be related to the change in body fat distribution in the elderly, i.e., more abdominal fat accumulation, the mechanism of which is unclear.MS is growing faster in the elderly and has become a common disease in the elderly. There is no uniform standard for the treatment of MS, and the current recommended protocols of various health organizations start with the prevention and treatment of various risk factors, such as the MS treatment guideline protocols issued by the US Cholestrol Education Program: weight loss, exercise, and dealing with individual risk factors, etc. The treatment protocols for hypertension and dyslipidemia are consistent with the general treatment protocols, and the use of glitazones in the treatment of DM is recommended. All treatment options lack evidence-based medical identification for the time being, but their main therapeutic aim is to reduce the incidence of cardiovascular disease. For example, the choice of tartans or clofibrates for lipid lowering can reduce the incidence of cardiovascular disease by 25-60% [3]. The treatment of metabolic syndrome in the elderly includes primary prevention and treatment based on lifestyle interventions and secondary prevention and treatment with lipid regulation, antihypertensive, glycemic control, anticoagulation and other pharmacological treatments.